Orgenesis to Present at NobleCon 14th Annual Institutional Investor Conference
GERMANTOWN, Md., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Orgenesis Inc., (OTCQB:ORGS), a vertically-integrated biopharmaceutical company with expertise and unique experience in gene and cell therapy production and regenerative medicine, announced that it will be presenting at the NobleCon 14th Annual Institutional Investor Conference being held January 29 - 30, 2018 in Ft. Lauderdale, FL. Robert Beckman, Director of Business Development for Orgenesis, will be giving a presentation and meeting with investors.
Event: NobleCon 14th Annual Institutional Investor Conference
Date: Tuesday, January 30, 2017
Time: 3:00 PM ET
Location: W Fort Lauderdale Beach Hotel, Ft. Lauderdale, FL
For investors attending the NobleCon conference, please contact Orgenesis Investor Relations to schedule a meeting with management at firstname.lastname@example.org.
A high-definition video webcast of the presentation will be available the following day on the Company's web site, www.orgenesis.com, and as part of a complete catalog of presentations available at Noble Capital Market’s website’s at www.noblecapitalmarkets.com and www.nobleconference.com. The webcast and presentation will be archived on the Company's website and on Noble Capital Market’s websites for 90 days following the event.
About Noble Capital Markets, Inc.
Noble Capital Markets, Inc., established in 1984, is an equity-research-driven, full-service, investment & merchant banking firm focused on the healthcare, media & entertainment, technology, transportation & logistics and natural resources sectors. The company has offices in Boca Raton, New York, Boston and St. Louis. In addition to NobleCon - the annual multi-sector investor conference - and the Media, Finance & Investor Program, produced in partnership with the National Association of Broadcasters (NAB) and held each spring in Las Vegas, throughout the year Noble Capital Markets hosts numerous “non-deal” corporate road shows across the United States and Canada. For more information, visit www.noblecapitalmarkets.com.
About Orgenesis Inc.
Orgenesis Inc. (Orgenesis) is a vertically-integrated biopharmaceutical company with expertise and unique experience in cell therapy development and manufacturing. Through its Israeli subsidiary, Orgenesis Ltd., Orgenesis is a pioneer in the development of technology designed to successfully reprogram human liver cells into glucose-responsive, fully functional, Insulin Producing Cells (IPCs). Orgenesis believes that converting the diabetic patient's own tissue into insulin-producing cells has the potential to overcome the significant issues of donor shortage, cost and exposure to chronic immunosuppressive therapy associated with islet cell transplantation. Through its Belgian subsidiary, MaSTherCell S.A., a global Contract Development and Manufacturing Organization (CDMO), Orgenesis is able to deliver optimized process industrialization capacities to cell therapy organizations, and speed up the arrival of their therapies onto the market. From technology selection to business modeling, GMP manufacturing, process development, quality management and assay development, MaSTherCell's teams are fully committed to helping their clients fulfill their objective of providing sustainable and affordable therapies to their patients. MaSTherCell operates in a validated and flexible facility located in the strategic center of Europe within the Walloon healthcare cluster, Biowin. Orgenesis is in the process of consolidating into its reformed corporate structure its Israel-based CDMO partner, At-Vio Biotech Ltd., and its Korean based CDMO partner, Curecell Co. Ltd., thereby expanding globally the availability of the MaSTherCell brand and service offering. This global integrated approach supports the Company's business philosophy of bringing to market significant life-improving medical treatments. For more information, visit www.orgenesis.com.
(investors) Tirth Patel
Released January 29, 2018